COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management

References

• Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–297.
   PubMed Web of Science ®Google Scholar
• Campbell N. 2020. OD: Naloxone and the Politics of Overdose. Cambridge, MA: MIT Press.
   Google Scholar
• Hansen H, Netherland H. Is the prescription opioid epidemic a white problem? Am J Public Health. 2016;106(12):2127–2129.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Substance Administration. 2020. Double Jeopardy: COVID-19 and behavioral health disparities for Black and Latino communities in the U.S. Washington, DC. https://www.samhsa.gov/sites/default/files/covid19-behavioral-health-disparities-black-latino-communities.pdf. Accessed May 18, 2020.
   Google Scholar
• Nouri S, Khoong EC, Lyles CR, Karliner L. Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic. NEJM Catalyst Innovations in Care Delivery. 2020;1(3). https://catalyst.nejm.org/doi/pdf/10.1056/CAT.20.0123
   Google Scholar
• John Hopkins University. COVID-19 map-Johns Hopkins Coronavirus Resource Center; 2020. https://coronavirus.jhu.edu/covid-19-daily-video.
   Google Scholar
• San Francisco Department of Public Health. Tracking COVID-19 in San Francisco. https://data.sfgov.org/stories/s/dak2-gvuj.
   Google Scholar
• Thadani T. If COVID-19 isn’t driving a dramatic increase in homeless deaths in SF, then what is? San Francisco Chronicle. August 19, 2020. https://www.sfchronicle.com/politics/article/If-COVID-19-isn-t-driving-a-dramatic-increase-15493665.php.
   Google Scholar
• Thadani T. More than one person a day died in SF of an overdose last year. This year is expected to be worse. San Francisco Chronicle. August 31, 2020. https://www.sfchronicle.com/politics/article/More-than-one-person-a-day-died-in-SF-of-an-15529006.php.
   Google Scholar
• American Society of Addiction Medicine. Caring for patients during the COVID-19 pandemic: ASAM COVID-19 Task Force recommendations. https://www.asam.org/docs/default-source/covid-19/drug-testing-guidance_042820.pdf?sfvrsn=ff854c2_2. Accessed May 18, 2020.
   Google Scholar
• Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. The Lancet. 2020;395(10227):912–920.
   PubMed Web of Science ®Google Scholar
• National Health Care for the Homeless Council. Reducing harm for people using drugs & alcohol during the COVID-19 pandemic: a guide for alternate care sites programs [Internet]. National Health Care for the Homeless Council; 2020 April. https://nhchc.org/wp-content/uploads/2020/04/Reducing-Harm-During-COVID-19-for-People-Using-Drugs-at-ACS1.pdf. Accessed May 10, 2020.
   Google Scholar
• Substance Abuse and Mental Health Substance Administration. FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. Washington, DC. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed May 10, 2020.
   Google Scholar
• Brico E. 2020. The pandemic is restricting health options for people who use drugs; 2020. Filter Magazine. https://filtermag.org/coronavirus-health-drugs/. Accessed May 10, 2020.
   Google Scholar
• American Society of Addiction Medicine. Caring for Patients During the COVID-19 Pandemic: ASAM COVID-19 Task Force Recommendations; 2020. https://www.asam.org/docs/default-source/covid-19/drug-testing-guidance_042820.pdf?sfvrsn=ff854c2_2. Accessed May 18, 2020.
   Google Scholar
• Substance Abuse and Mental Health Substance Administration. Considerations for the care and treatment of mental and susbtance use disorders in the COVID-19 epidemic; 2020. https://www.samhsa.gov/sites/default/files/considerations-care-treatment-mental-substance-use-disorders-covid19.pdf. Accessed May 18, 2020.
   Google Scholar
• Lin CCC, Dievler A, Robbins C, Sripipatana A, Quinn M, Nair S. Telehealth in health centers: key adoption factors, barriers, and opportunities. Health. Health Aff. 2018;37(12):1967–1974.
   PubMed Web of Science ®Google Scholar
• San Francisco Department of Public Health. 2020. Order of the health officer No.C19-07b. https://www.sfdph.org/dph/alerts/files/HealthOfficerOrder-C19-07b-ShelterInPlace-03312020.pdf.
   Google Scholar
• California Department of Public Health. COVID-19 updates. Getting health care from home through Telehealth; 2020. https://covid19.ca.gov/telehealth/. Accessed May 18, 2020.
   Google Scholar
• Metzl JM, Hansen H. Structural competency: theorizing a new medical engagement with stigma and inequality. Social Science & Medicine. 2014;103:126–133.
   PubMed Web of Science ®Google Scholar
• Metzl JM, Roberts DE. Structural competency meets structural racism: race, politics, and the structure of medical knowledge. AMA Journal of Ethics. 2014;16(9):674–690.
   Google Scholar
• Kulesza M, Matsuda M, Ramirez JJ, Werntz AJ, Teachman BA, Lindgren KP. Towards greater understanding of addiction stigma: Intersectionality with race/ethnicity and gender. Drug Alcohol Depend. 2016;169:85–91.
   PubMed Web of Science ®Google Scholar
• Thadani T. San Francisco homeless deaths soar – and officials say it’s not directly due to COVID-19. San Francisco Chronicle. May 26, 2020. https://www.sfchronicle.com/politics/article/San-Francisco-homeless-deaths-soar-and-it-s-15295730.php.
   Google Scholar
• Molfenter T, Boyle M, Holloway D, Zwick J. Trends in telemedicine use in addiction treatment. Addict Sci Clin Pract. 2015;10(1):14.
   PubMedGoogle Scholar
• Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612–617.
   PubMed Web of Science ®Google Scholar
• Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abuse Treat. 2019;101:38–49.
   PubMed Web of Science ®Google Scholar
• Tofighi B, Abrantes A, Stein MD. The role of technology-based interventions for substance use disorders in primary care: a review of the literature. Med Clin North Am. 2018;102(4):715–731.
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Busch AB, Souza J, Uscher-Pines L, et al. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff. 2018;37(12):1940–1947.
   PubMed Web of Science ®Google Scholar
• Creedon TB, Schrader KE, O'Brien PL, Lin JR, Carroll CD, Mulvaney-Day N. Rural-nonrural differences in telemedicine use for mental and substance use disorders among medicaid beneficiaries. PS. 2020;71(8):756–764.
   Google Scholar
• Molfenter T, Brown R, O’Neill A, Kopetsky E, Toy A. Use of telemedicine in addiction treatment: current practices and organizational implementation characteristics. International J Telemed Appl. 2018;2018:1–7.
   Web of Science ®Google Scholar
• Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
   PubMed Web of Science ®Google Scholar